ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / DRUG / news
PBYI (70) EVO (47) NGNE (36) STTK (29) ⌘ Pro Terminal →

Why DRUG Stock dropped -52.35% Today — RQD Quant Desk Flash

$26.20 -52.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.68

Bright Minds Biosciences Inc. (DRUG) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $539.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DRUG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DRUG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Bright Minds Biosciences Inc. (NASDAQ: DRUG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $26.20 (-52.35% 1D, market cap $539.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, DRUG ranks #330 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DRUG compare to PBYI and EVO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DRUG carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PBYI (Puma Biotechnology Inc) holds a B- grade (70/100 RQD, P/E 17.5x, ROIC 29.3%, cap $538.9M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DRUG?
▼

For Bright Minds Biosciences Inc. (DRUG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #330 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $23.68 (-9.61%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (12)Whales (5)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$130 Bull$25 Base$19 Bear
📬 FREE DRUG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRUG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY DRUG SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$51.36+7.5% Next Q
Q2 (-2Q)
51
Grade C-$55.20-2.1% Next Q
Q3 (-1Q)
49
Grade D$54.02-51.5% Next Q
Current
46
Grade D$26.20-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRUG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRUG currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($58.33) and Max Pain ($27.51) forces dealer call-delta covering toward $129.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRUG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DRUG Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why DRUG Stock dropped -52.35% Today — RQD Quant Desk Flash

Bright Minds Biosciences Inc. (DRUG) dropped -52.35% to $26.20, trading at 2% of its 52-week range ($47.23 – $123.75). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($47.23 – $123.75) with RSI-14 at 50 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $26.20 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $15.1M annual free cash flow.
Live DRUG Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRUG)

  • ✓Walkthrough of DRUG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DRUG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.53%▼ SUPPORT BREAKDOWN
2026-11-03O $56.69H $56.69L $26.20C $26.20VOL 95.8K
RES: $82.43SUP: $38.87SMA50: $58.33SMA200: $72.93
$96.61$77.52$58.44$39.36$20.28RES $82.43SUP $38.87$26.202026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRUG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRUG Butterfly Map → + Track DRUG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DRUG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRUG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DRUG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRUG)

Health Care Rank #330 of 1015 ⚔️ PBYI vs DRUG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRUG vs. PBYI, EVO, NGNE, STTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bright Minds Biosciences Inc. (DRUG) ranks #330 by composite RQD confidence (46/100, grade D) and #428 by equity capitalization ($539.9M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with DRUG at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DRUG ACTIVE
Bright Minds Biosciences Inc.
D 46/100 — — — -52.35% $539.9M Benchmark Subject
PBYI
Puma Biotechnology Inc
B- 70/100 17.5x 74.5% 29.3% -2.49% $538.9M /pbyi-vs-drug →
EVO
Evotec SE
D 47/100 — — — -0.65% $544.3M /evo-vs-drug →
NGNE
Neurogene Inc.
D- 36/100 — — -35.0% -3.41% $551.3M /ngne-vs-drug →
STTK
Shattuck Labs Inc.
E 29/100 — — -35.0% -4.32% $558.0M /sttk-vs-drug →

2. DRUG Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Bright Minds Biosciences Inc. (DRUG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $539.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. DRUG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRUG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bright Minds Biosciences Inc. (NASDAQ: DRUG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $26.20 (-52.35% 1D, market cap $539.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, DRUG ranks #330 in composite RQD confidence.

How does DRUG compare to PBYI and EVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DRUG carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PBYI (Puma Biotechnology Inc) holds a B- grade (70/100 RQD, P/E 17.5x, ROIC 29.3%, cap $538.9M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $544.3M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRUG?

For Bright Minds Biosciences Inc. (DRUG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #330 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRUG trading relative to its 50-day, 200-day, and 52-week technical levels?

DRUG last traded at $26.20 (-52.35% on volume of 1,827,495 shares), positioning the stock -55.08% below its 50-day simple moving average ($58.33) and -64.08% below its 200-day simple moving average ($72.93). Across its 52-week range of $47.23 to $123.75, DRUG sits at the 0.0% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($22.93 to $29.47).

Direct Sub-Reports: DRUG RQD Cockpit DRUG 12M Forecast DRUG Earnings & Move DRUG Dividends & DRIP DRUG Insiders & 13F DRUG Whale Options DRUG Profit Sankey DRUG News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

DRUG — Bright Minds Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bright Minds Biosciences Inc. (DRUG) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $26.20 (-52.35% 1D, market capitalization $539.9M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bright Minds Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — The profile does not describe its products, customers, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $47.23 – $123.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), DRUG carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can DRUG sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $123.75 52-week high?
  • Key Question #3: How sensitive is DRUG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DRUG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bright Minds Biosciences Inc. (DRUG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DRUG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DRUG Bull vs. Bear Conversation Board — What's Your Call at $26.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DRUG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DRUG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $68.18 (+24.0%)
📌 Pinned Debate

Forensic balance-sheet pillar scores 13/20 with Altman Z 2.5 and Piotroski F 6/9, the strongest component of the rating.

Here is why I am bullish on DRUG here at $54.98: Forensic balance-sheet pillar scores 13/20 with Altman Z 2.5 and Piotroski F 6/9, the strongest component of the rating.. Compare DRUG's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $52.23 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — DRUG's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $42.88 (-22.0%)
Spot @ $54.98

ROIC and FCF yield are both 0% and whale 13F flow scores only 5/20, with the rating verdict labeled as distribution warning.

I respect the product at Bright Minds Biosciences Inc., but the stock at $54.98 is a different story. ROIC and FCF yield are both 0% and whale 13F flow scores only 5/20, with the rating verdict labeled as distribution warning.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE